Assessment of Rheumatologic Tolerability of Letrozole in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer Having Discontinued Anastrozole Adjuvant Treatment Due to Musculoskeletal Disorders
Interventional
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To evaluate the rheumatological tolerability of letrozole 2.5 mg/day in patients treated with anastrozole 1 mg/day
at 1, 3 and 6 months of letrozole treatment
No
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
CFEM345DFR04
NCT00329940
November 2005
Name | Location |
---|